Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Genmab  /  Forum Genmab geopend

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel GENMAB AS CHX:GMAB_C.CXE3, DK0010272202

  • 2.085,500 11 apr 2024 15:48
  • 0,000 (0,00%) Dagrange 0,000 - 0,000
  • 0

Forum Genmab geopend

34 Posts
Pagina: «« 1 2 | Laatste | Omlaag ↓
  2. forum rang 4 aossa 1 juli 2020 11:59
    Genmab Announces Very Favorable Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
    Company Announcement
    • Genmab and Seattle Genetics plan to discuss the results with the U.S. Food and Drug Administration (U.S. FDA)
    • Full data to be presented at an upcoming medical meeting
    Copenhagen, Denmark; June 29, 2020 – Genmab A/S (Nasdaq: GMAB) today announced very favorable topline results from the Phase 2 single-arm clinical trial known as innovaTV 204 evaluating tisotumab vedotin administered every three weeks for the treatment of patients who have relapsed or progressed on or after prior treatment for recurrent or metastatic cervical cancer. Results from the trial showed a 24 percent confirmed objective response rate (ORR) by independent central review (95% Confidence Interval: 15.9% - 33.3%) with a median duration of response (DOR) of 8.3 months. The most common treatment-related adverse events (greater than or equal to 20 percent) included alopecia, epistaxis (nose bleeds), nausea, conjunctivitis, fatigue and dry eye. The data will be submitted for presentation at an upcoming medical meeting.
    Tisotumab vedotin is an investigational antibody-drug conjugate (ADC) directed to tissue factor, which is expressed on cervical cancer and can promote tumor growth, angiogenesis and metastases.1 Standard therapies for previously treated recurrent and/or metastatic cervical cancer generally result in limited objective response rates of typically less than 15 percent with median overall survival ranging from 6.0 to 9.4 months, in an all-comers population.1-8 Tisotumab vedotin is being developed in collaboration with Seattle Genetics.
    “After treatment with first-line chemotherapy regimens, there is a high unmet need for new effective and tolerable treatment options for women with advanced cervical cancer, regardless of biomarkers and histology,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. “These promising topline data from innovaTV 204 will be the basis of further engagement with the U.S. FDA as we continue to progress and expand our tisotumab vedotin development program in solid tumors with our partner.”
    Additional clinical trials of tisotumab vedotin are currently enrolling patients, including in combination with pembrolizumab, carboplatin or bevacizumab, and with a weekly dosing schedule in patients with locally advanced or metastatic cervical cancer. Tisotumab vedotin is also being evaluated in other tissue factor expressing tumor types, including ovarian and other solid tumors.
    About innovaTV 204 Trial
    The innovaTV 204 trial (also known as GCT1015-04 or innovaTV 204/GOG-3023/ENGOT-cx6) is an ongoing single-arm, global, multicenter study of tisotumab vedotin for patients with recurrent or metastatic cervical cancer who were previously treated with doublet chemotherapy with bevacizumab if eligible per local standards. Additionally, patients were eligible if they had received up to two prior lines of therapy in the metastatic setting. In the study operationalized by Genmab, 101 patients were treated with tisotumab vedotin at multiple centers in the U.S. and Europe. The primary endpoint of the trial was confirmed objective response rate per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by independent central review. Key secondary endpoints included duration of response, progression-free survival, overall survival, safety and tolerability.
    The study was conducted by Genmab in collaboration with Seattle Genetics Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT) and Gynecologic Oncology Group (GOG). For more information about the Phase 2 innovaTV 204 clinical trial and other clinical trials with tisotumab vedotin, please visit www.clinicaltrials.gov.
  4. demo44 8 juli 2020 13:56
    Goed nieuws

    FDA lifts partial hold on mid-stage study of ADC Therapeutics' camidanlumab tesirine
    Jul. 6, 2020 8:10 AM ET|About: ADC Therapeutics SA (ADCT)|By: Douglas W. House, SA News Editor
    The FDA has removed its partial clinical hold on a pivotal Phase 2 clinical trial evaluating ADC Therapeutics' (NYSE:ADCT) antibody-drug conjugate camidanlumab tesirine in patients with relapsed/refractory Hodgkin lymphoma.

    The company says it "worked diligently" to provide responses to the agency's request for information but does disclose the specific nature of the request.

    A partial clinical hold suspends recruitment but allows current participants to continue treatment.

    Camidanlimab tesirine is comprised of a CD25-targeting monoclonal antibody in-licensed from Genmab A/S (NASDAQ:GMAB) linked to tesirine, the pyrrolobenzodiazepine (PBD) dimer payload.

  13. priscillaaaa 4 november 2021 21:30
    Genmab Improves its 2021 Financial Guidance

    Genmab’s projected revenue for 2021 primarily consists of DARZALEX royalties. Such royalties are based on Genmab’s revised estimate of DARZALEX 2021 net sales of USD 5.9–6.2 billion compared to Genmab’s previous estimate of USD 5.6-5.9 billion.

    Goed nieuws, morgen opnieuw omhoog!
  14. forum rang 10 DeZwarteRidder 3 april 2024 13:15
    Genmab neemt ProfoundBio over
    03-04-2024 08:26 - Voor 1,8 miljard dollar in contanten.

    (ABM FN-Dow Jones) Het Deense Genmab wil voor 1,8 miljard dollar ProfoundBio inlijven. Dit maakte Genmab woensdagochtend bekend.

    Met deze acquisitie verwerft Genmab drie kandidaatmedicijnen, onder meer tegen eierstokkanker, en het technologische platform van Profoundbio.

    De transactie heeft de goedkeuring van de commissarissen van beide ondernemingen en zal naar verwachting afgerond worden in de eerste helft van dit jaar.

    Door: ABM Financial News.
34 Posts
Pagina: «« 1 2 | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!